Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study

Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study

ObjectivesEtrasimod is an investigational, oral, once-daily, selective S1P1,4,5 receptor modulator in development for the treatment of immune-mediated inflammatory diseases. We present safety, tolerability, pharmacokinetic, and pharmacodynamic results of etrasimod treatment in healthy Chinese adults...

Full description

Saved in:
Bibliographic Details
Main Authors: Fangfang Wang, Xiaoye Niu, Na Liu, Zhengying Zhu, Yun Lin, Lisa Ying, Haiyan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
etrasimod
sphingosine 1-phosphate receptor (S1PR)
inflammatory bowel disease (IBD)
lymphocytes
immune-mediated inflammatory diseases (IMID)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1523339/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1523339/full

Similar Items